Immutep's IMP-761, a LAG-3 agonist, demonstrates a favorable safety profile in Phase I trials, potentially addressing autoimmune diseases like rheumatoid arthritis.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.